Treatment
Irinotecan clinical trials
We’re tracking 200 recruiting studies that include Irinotecan, each written for real people, not researchers, below.
Recruiting studies
- NCT07466316RecruitingPhase 3
Comparing chemo schedules for intermediate-risk rhabdomyosarcoma
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
Birmingham, AlabamaAges Up to 50 years - NCT07463573RecruitingPhase 3
New drug vs chemotherapy for advanced esophageal cancer
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07441369Enrolling by invitationPhase 2
Abemaciclib with chemotherapy for advanced colorectal liver metastases
This trial tests combining the targeted drug abemaciclib with standard chemotherapy (FOLFOX or FOLFIRI) for people whose colorectal cancer has spread to the liver and cannot be removed surgically. It may be an option if you've already tried two or three prior treatments without success.
ShanghaiAges 18–75 - NCT05472259RecruitingPhase 2
Testing two chemotherapy combos for metastatic pancreatic cancer
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
Antwerp, AntwerpAges 18 years+ - NCT07415031RecruitingPhase 2
Long term treatment with adagrasib for solid tumor patients
This trial allows people with solid tumors who are already benefiting from the study drug adagrasib in an earlier Mirati study to continue getting it for the long term. It’s for people whose doctors see ongoing benefit and who still meet the safety rules.
Phoenix, ArizonaAges 18 years+ - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT06816914RecruitingPhase 2
Perioperative chemo for resectable pancreatic cancer
This trial tests a combination of chemotherapy drugs (liposomal irinotecan with fluorouracil, leucovorin, and oxaliplatin) given before and after surgery for pancreatic cancer that can be fully removed. It aims to see if this approach improves outcomes for patients with stage I or II disease.
Kaohsiung CityAges 20–75 - NCT07346157RecruitingPhase 1/Phase 2
Testing a thyroid hormone drug with chemo for relapsed medulloblastoma
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
San Francisco, CaliforniaAges 1–25 - NCT07334301RecruitingPhase 1/Phase 2
Combination treatments for relapsed high-risk neuroblastoma
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
SydneyAges 1 year+ - NCT07328425RecruitingPhase 2
A study of lurbinectedin and irinotecan for advanced DSRCT
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
Candiolo, TorinoAges 15 years+ - NCT07289997RecruitingPhase 2
Combination therapy for advanced AFP-producing gastric cancer
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (apatinib) and a chemotherapy drug (irinotecan hydrochloride) for people with a rare type of advanced stomach cancer called AFP-producing gastric cancer. It is for patients whose cancer did not respond to previous immunotherapy combined with chemotherapy.
Shijiazhuang, HebeiAges 18 years+ - NCT07284134RecruitingPhase 3
JS107 vs standard therapy for advanced stomach cancer
This trial tests a new drug, JS107, against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has continued to grow after at least one prior treatment. The cancer must have a specific protein called CLDN18.2 on its cells.
Hefei, AnhuiAges 18 years+ - NCT07271355RecruitingPhase 3
Pressurized chemo spray for appendix or colorectal cancer spread in abdomen
This trial tests a new way to deliver chemotherapy directly into the abdomen as a pressurized spray, using a drug called mitomycin. It is for people with appendix or colorectal cancer that has spread to the lining of the abdomen and cannot be removed by surgery.
Goodyear, ArizonaAges 18 years+ - NCT06894797Recruiting
Chemo and radiation before and after surgery for rectal cancer
This study tests a sequence of chemotherapy and radiation before and after surgery for rectal cancer. It compares giving more chemo between the end of radiation and surgery (consolidation) versus giving some chemo before radiation starts (induction). The goal is to see which order works better.
BeijingAges 18–75 - NCT07235202RecruitingPhase 1/Phase 2
MR001 plus chemo for advanced pancreatic cancer after first treatment
This trial tests a new drug, MR001, combined with chemotherapy for people whose pancreatic cancer has spread and no longer responds to their first treatment. It aims to see if this combination can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT07214298RecruitingPhase 1/Phase 2
Combination treatment for advanced pancreatic cancer
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
Buffalo, New YorkAges 18 years+ - NCT06928584RecruitingPhase 2
Shorter Radiation Plus Immunotherapy for Recurrent Rectal Cancer
This trial tests whether a shorter, higher-dose radiation course (hypofractionated) combined with immunotherapy works better than standard radiation for locally recurrent rectal cancer that hasn't spread elsewhere. It's for people who haven't had chemotherapy or recent pelvic radiation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07204574RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer after first treatment
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
TaoyuanAges 18 years+ - NCT07194044RecruitingPhase 1
Testing a treatment schedule for metastatic Ewing sarcoma
This trial tests a new schedule of standard chemotherapy drugs to see if it improves outcomes for people with metastatic Ewing sarcoma or CIC-rearranged sarcoma. It is for patients who have not had prior cancer treatment, except possibly one initial cycle of VDC.
Birmingham, AlabamaAges 1 year+ - NCT05978492RecruitingPhase 1
Study of TXN10128 for advanced solid tumors
This trial is testing a new drug, TXN10128, for people with advanced solid tumors that have stopped responding to other treatments. It may be an option if standard treatments haven't worked or aren't suitable.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07183865RecruitingPhase 2
Radiation, chemo, and immunotherapy for recurrent rectal cancer
This trial tests a new combination of radiation, chemotherapy (NALIRIF), and an immunotherapy drug (PD-1 antibody) for rectal cancer that has come back in the pelvis. The goal is to see if this approach can help control the cancer better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07150247RecruitingPhase 2
Study of IB-FOLFIRI for advanced colon cancer with BRAF V600E mutation
This trial tests a new combination of drugs (IB-FOLFIRI) for people with metastatic colorectal cancer that has a specific gene change called BRAF V600E. It is for those whose cancer has grown after at least one prior treatment and who have not had irinotecan stop working.
Guangzhou, GuangdongAges 18–75 - NCT07096362RecruitingPhase 2
Using a blood test to guide treatment for advanced pancreatic cancer
This trial tests whether a blood test that detects tumor DNA can help doctors decide early if the standard chemotherapy is working, and if switching treatment might be better. It is for people newly diagnosed with metastatic pancreatic cancer who are starting their first chemotherapy.
Miami, FloridaAges 18 years+ - NCT07085338RecruitingPhase 2
N-803 with chemoimmunotherapy for relapsed neuroblastoma
This trial tests adding a new drug called N-803 to a standard chemo-immunotherapy combination for children and young adults with high-risk neuroblastoma that has come back or not responded to previous treatments. The goal is to see if this combination works better at fighting the cancer.
San Francisco, CaliforniaAges Up to 30 years
Common questions
- Are there clinical trials studying Irinotecan?
- Yes. Clin2 currently lists 200 recruiting studies that include Irinotecan, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Irinotecan trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Irinotecan an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Irinotecan or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.